Canaccord Genuity analyst Richard Close maintained a Buy rating on Teladoc (NYSE:TDOC) on Wednesday, setting a price target of $330, which is approximately 29.65% above the present share price of $254.53.
Close expects Teladoc to post earnings per share (EPS) of -$0.43 for the first quarter of 2021.
The current consensus among 16 TipRanks analysts is for a Moderate Buy rating of shares in Teladoc, with an average price target of $251.33.
The analysts price targets range from a high of $330 to a low of $200.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $288.81 million and a net profit of $5.67 million. The company's market cap is $36.9 billion.
According to TipRanks.com, Canaccord Genuity analyst Richard Close is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 31.9% and a 62.65% success rate.
Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Purchase, NY.